BioWorld

Feb. 13, 2009

View Archived Issues

Portola's Anticlotting Drug Gains Partner in Potential $575M Deal

In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today) Read More

Futility Analysis Derails BioMarin and LJP's Phase III Riquent Trial

Read More

Better Blood Supply Leads to Better-Behaved Tumors

Read More

Insmed Jumps on Merck $130M Bid for FOBs Drugs

Read More

Holiday Notice

Read More

Corrections & Clarifications

Read More

Alios Closes $8.4M Tranche of $24M Series A Round

Read More

Oscient and Telik Cut Deep to Conserve Capital

Read More

Novelos, Mundipharma Sign $95M Deal for Cancer Drug

Read More

Appointments And Advancements

Read More

Other News To Note

Read More

Clinic Roundup

Read More